title: ÐÐ»Ð¾Ð½Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ðµ Ð³ÐµÐ½Ð° Ð¿Ð¾Ð²ÐµÑÑ Ð½Ð¾ÑÑÐ½Ð¾Ð³Ð¾ Ð»Ð¸Ð¿Ð¾Ð¿ÑÐ¾ÑÐµÐ¸Ð½Ð° ÑÑÑÐµÐ¿ÑÐ¾ÐºÐ¾ÐºÐºÐ° Ð³ÑÑÐ¿Ð¿Ñ Ð Ð² Ð³ÐµÐ½ NS Ñ Ð¾Ð»Ð¾Ð´Ð¾Ð°Ð´Ð°Ð¿ÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð½Ð¾Ð³Ð¾ Ð²Ð¸ÑÑÑÐ° Ð³ÑÐ¸Ð¿Ð¿Ð°
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: Cloning of the group B streptococcus surface lipoprotein gene into the cold-adapted influenza virus NS gene
Creators: name: Ð¦Ð¸Ð¼Ð¼ÐµÑÐ¼Ð°Ð½, ÐÐºÐ°ÑÐµÑÐ¸Ð½Ð°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2020
Subjects: Ð¶Ð¸Ð²Ð°Ñ Ð³ÑÐ¸Ð¿Ð¿Ð¾Ð·Ð½Ð°Ñ Ð²Ð°ÐºÑÐ¸Ð½Ð°
ÑÑÑÐµÐ¿ÑÐ¾ÐºÐ¾ÐºÐºÐ¸ Ð³ÑÑÐ¿Ð¿Ñ Ð
Ð³ÐµÐ½ Ð¿Ð¾Ð²ÐµÑÑ Ð½Ð¾ÑÑÐ½Ð¾Ð³Ð¾ Ð»Ð¸Ð¿Ð¾Ð¿ÑÐ¾ÑÐµÐ¸Ð½Ð° Sca
Ð²ÐµÐºÑÐ¾ÑÐ½Ð°Ñ Ð²Ð°ÐºÑÐ¸Ð½Ð°
Ð½Ð°Ð¿ÑÐ°Ð²Ð»ÐµÐ½Ð½ÑÐ¹ ÑÐ¸Ð½ÑÐµÐ· ÑÑÐ¶ÐµÑÐ¾Ð´Ð½Ð¾Ð³Ð¾ Ð±ÐµÐ»ÐºÐ°
live influenza vaccine
group B streptococci
Sca surface lipoprotein gene
vector vaccine aimed at synthesizing foreign protein

description: ÐÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ° Ð¿Ð¾ÑÐ²ÑÑÐµÐ½Ð° ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐºÐµ Ð½Ð¾Ð²Ð¾Ð³Ð¾ Ð¿Ð¾Ð´ÑÐ¾Ð´Ð° Ð´Ð»Ñ ÑÐ¾Ð·Ð´Ð°Ð½Ð¸Ñ Ð¿ÑÐ¾ÑÐ¾ÑÐ¸Ð¿Ð¾Ð² Ð²Ð¸ÑÑÑÐ½Ð¾-Ð±Ð°ÐºÑÐµÑÐ¸Ð°Ð»ÑÐ½Ð¾Ð¹ Ð²ÐµÐºÑÐ¾ÑÐ½Ð¾Ð¹ Ð²Ð°ÐºÑÐ¸Ð½Ñ Ð½Ð° Ð¾ÑÐ½Ð¾Ð²Ðµ ÑÑÐ°Ð¼Ð¼Ð¾Ð² Ð´Ð»Ñ Ð¶Ð¸Ð²Ð¾Ð¹ Ð³ÑÐ¸Ð¿Ð¿Ð¾Ð·Ð½Ð¾Ð¹ Ð°ÑÑÐµÐ½ÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð½Ð¾Ð¹ ÑÐµÐ°ÑÑÐ¾ÑÑÐ°Ð½ÑÐ½Ð¾Ð¹ Ð²Ð°ÐºÑÐ¸Ð½Ñ (ÐÐÐ). Ð Ð¿ÑÐ¾ÑÐµÑÑÐµ ÑÐ°Ð±Ð¾ÑÑ Ð±ÑÐ» Ð¿ÑÐ¾Ð²ÐµÐ´ÐµÐ½ Ð³Ð»ÑÐ±Ð¾ÐºÐ¸Ð¹ Ð°Ð½Ð°Ð»Ð¸Ð· ÑÐ¾Ð²ÑÐµÐ¼ÐµÐ½Ð½Ð¾Ð¹ Ð»Ð¸ÑÐµÑÐ°ÑÑÑÑ Ð¿Ð¾ ÑÐ¾ÑÑÐ¾ÑÐ½Ð¸Ñ Ð¿ÑÐ¾Ð±Ð»ÐµÐ¼Ð°ÑÐ¸ÐºÐ¸ Ð²ÐµÐºÑÐ¾ÑÐ½ÑÑ Ð²Ð°ÐºÑÐ¸Ð½ Ð½Ð° ÑÐµÐºÑÑÐ¸Ð¹ Ð¼Ð¾Ð¼ÐµÐ½Ñ, Ð° ÑÐ°ÐºÐ¶Ðµ ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐºÐ¸ Ð¾ÑÐ´ÐµÐ»Ð° Ð²Ð¸ÑÑÑÐ¾Ð»Ð¾Ð³Ð¸Ð¸ Ð¸Ð¼.Ð.Ð.Ð¡Ð¼Ð¾ÑÐ¾Ð´Ð¸Ð½ÑÐµÐ²Ð° Ð² ÐÐ½ÑÑÐ¸ÑÑÑÐµ Ð­ÐºÑÐ¿ÐµÑÐ¸Ð¼ÐµÐ½ÑÐ°Ð»ÑÐ½Ð¾Ð¹ ÐÐµÐ´Ð¸ÑÐ¸Ð½Ñ Ð¿Ð¾ ÑÐ¾Ð·Ð´Ð°Ð½Ð¸Ñ ÑÑÐ´Ð° Ð²ÐµÐºÑÐ¾ÑÐ½ÑÑ Ð²Ð°ÐºÑÐ¸Ð½ Ð¿ÑÐ¾ÑÐ¸Ð² ÑÐ°Ð·Ð»Ð¸ÑÐ½ÑÑ Ð¸Ð½ÑÐµÐºÑÐ¸Ð¾Ð½Ð½ÑÑ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ð¹. ÐÑÐ»Ð¾ Ð¾Ð¿ÑÐµÐ´ÐµÐ»ÐµÐ½Ð¾, ÑÑÐ¾ Ð½Ð°Ð¸Ð±Ð¾Ð»ÐµÐµ Ð¿ÐµÑÑÐ¿ÐµÐºÑÐ¸Ð²Ð½Ð¾Ð¹ ÑÑÑÐ°ÑÐµÐ³Ð¸ÐµÐ¹ Ð´Ð»Ñ Ð²ÐµÐºÑÐ¾ÑÐ½Ð¾Ð¹ Ð²Ð°ÐºÑÐ¸Ð½Ñ Ð¿ÑÐ¾ÑÐ¸Ð² ÑÑÑÐµÐ¿ÑÐ¾ÐºÐ¾ÐºÐºÐ¾Ð²Ð¾Ð¹ Ð¸Ð½ÑÐµÐºÑÐ¸Ð¸ Ð±ÑÐ´ÐµÑ ÑÐ²Ð»ÑÑÑÑÑ Ð²ÑÑÑÐ°Ð¸Ð²Ð°Ð½Ð¸Ðµ Ð³ÐµÐ½ÐµÑÐ¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð¼Ð°ÑÐµÑÐ¸Ð°Ð»Ð° ÑÑÑÐµÐ¿ÑÐ¾ÐºÐ¾ÐºÐºÐ° Ð² Ð³ÐµÐ½ NS Ð´Ð¾Ð½Ð¾ÑÐ° Ð°ÑÑÐµÐ½ÑÐ°ÑÐ¸Ð¸ Ð´Ð»Ñ ÐÐÐ. ÐÐ»Ñ ÑÑÐ¾Ð³Ð¾ Ð±ÑÐ»Ð¸ ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐ°Ð½Ñ ÑÐ°Ð·Ð»Ð¸ÑÐ½ÑÐµ Ð´Ð¸Ð·Ð°Ð¹Ð½Ñ Ð´Ð»Ñ ÑÐ¸Ð¼ÐµÑÐ½Ð¾Ð³Ð¾ NS-Ð³ÐµÐ½Ð° Ñ Ð´Ð¾Ð±Ð°Ð²Ð»ÐµÐ½Ð¸ÐµÐ¼ Ð¿ÐµÐ¿ÑÐ¸Ð´Ð¾Ð² PADRE, LAMP-1, ÑÐ¸Ð³Ð½Ð°Ð»ÑÐ½Ð¾Ð³Ð¾ Ð¿ÐµÐ¿ÑÐ¸Ð´Ð° Ð¸ ÑÑÐ°Ð½ÑÐ¼ÐµÐ¼Ð±ÑÐ°Ð½Ð½Ð¾Ð³Ð¾ Ð´Ð¾Ð¼ÐµÐ½Ð° Ð7 Ð´Ð»Ñ Ð½Ð°Ð¿ÑÐ°Ð²Ð»ÐµÐ½Ð½Ð¾Ð³Ð¾ ÑÐ¸Ð½ÑÐµÐ·Ð° Ð±ÐµÐ»ÐºÐ° Ð² ÑÐ°Ð·Ð»Ð¸ÑÐ½ÑÐµ ÐºÐ¾Ð¼Ð¿Ð°ÑÐ¼ÐµÐ½ÑÑ ÐºÐ»ÐµÑÐºÐ¸. Ð ÐºÐ°ÑÐµÑÑÐ²Ðµ Ð¸Ð¼Ð¼ÑÐ½Ð¾Ð³ÐµÐ½Ð½ÑÑ Ð²ÑÑÐ°Ð²Ð¾Ðº ÑÑÑÐµÐ¿ÑÐ¾ÐºÐ¾ÐºÐºÐ° Ð±ÑÐ»Ð¸ Ð²ÑÐ±ÑÐ°Ð½Ñ ÑÑÐ°ÑÑÐºÐ¸ Ð¿Ð¾Ð²ÐµÑÑÐ½Ð¾ÑÑÐ½Ð¾Ð³Ð¾ Ð»Ð¸Ð¿Ð¾Ð¿ÑÐ¾ÑÐµÐ¸Ð½Ð° Sca Ð´Ð»Ð¸Ð½Ð¾Ð¹ 87, 141, 200 Ð¸ 287 Ð°Ð¼Ð¸Ð½Ð¾ÐºÐ¸ÑÐ»Ð¾Ñ, Ð½ÑÐºÐ»ÐµÐ¾ÑÐ¸Ð´Ð½Ð°Ñ Ð¿Ð¾ÑÐ»ÐµÐ´Ð¾Ð²Ð°ÑÐµÐ»ÑÐ½Ð¾ÑÑÑ ÐºÐ°Ð¶Ð´Ð¾Ð¹ Ð²ÑÑÐ°Ð²ÐºÐ¸ Ð±ÑÐ»Ð° Ð¿Ð¾Ð»ÑÑÐµÐ½Ð° Ð¼ÐµÑÐ¾Ð´Ð¾Ð¼ Ð¿ÐµÑÐµÐºÑÑÐ²Ð°ÑÑÐµÐ¹ÑÑ ÐÐ¦Ð . Ð ÑÐ°ÐºÐ¶Ðµ Ð¿Ð¾Ð»ÑÑÐµÐ½Ð° ÑÐ½Ð¸Ð²ÐµÑÑÐ°Ð»ÑÐ½Ð°Ñ Ð¿Ð»Ð°Ð·Ð¼Ð¸Ð´Ð° Ð´Ð»Ñ Ð¾Ð±ÑÐ°ÑÐ½Ð¾Ð¹ Ð³ÐµÐ½ÐµÑÐ¸ÐºÐ¸ ÑÐ¾ Ð²ÑÑÐ°Ð²ÐºÐ¾Ð¹ Ð¼Ð¾Ð´Ð¸ÑÐ¸ÑÐ¸ÑÐ¾Ð²Ð°Ð½Ð½Ð¾Ð³Ð¾ NS Ð³ÐµÐ½Ð° Ð´Ð»Ñ ÑÐ»ÐµÐ´ÑÑÑÐ¸Ñ ÑÑÐ°Ð¿Ð¾Ð² ÑÐ°Ð·ÑÐ°Ð±Ð¾ÑÐºÐ¸ Ð²ÐµÐºÑÐ¾ÑÐ½Ð¾Ð¹ Ð²Ð°ÐºÑÐ¸Ð½Ñ Ð¿ÑÐ¾ÑÐ¸Ð² ÑÑÑÐµÐ¿ÑÐ¾ÐºÐ¾ÐºÐºÐ¾Ð²Ð¾Ð¹ Ð¸Ð½ÑÐµÐºÑÐ¸Ð¸
description: The bachelorâs qualification work is devoted to the development of a new approach for prototyping a viral-bacterial vector vaccine based on strains for live influenza attenuated reassortant vaccine (VHV). In the process, an in-depth analysis of modern literature on the current state of the problems of vector vaccines was carried out, as well as the development of the A. A. Smorodintsev Virology Department at the Institute of Experimental Medicine to create a series of vector vaccines against various infectious diseases. It has been determined that the most promising strategy for a vector vaccine against streptococcal infection will be the incorporation of the genetic material of streptococcus into the NS gene of the attenuation donor for PLWH. For this, various designs were developed for the chimeric NS gene with the addition of the PADRE, LAMP-1 peptides, the signal peptide and the H7 transmembrane domain for targeted protein synthesis in various cell compartments. Sections of surface Sca lipoprotein 87, 141, 200 and 287 amino acids in length were selected as immunogenic streptococcus inserts; the nucleotide sequence of each insert was obtained by overlapping PCR. A universal plasmid for reverse genetics with the insertion of a modified NS gene for the next stages of the development of a vector vaccine against streptococcal infection was also obtained